How to follow-up patients with epithelial ovarian cancer

Current Opinion in Oncology

Volumn 22, Issue 5, 2010, Pages 498-502

  Miller, Rowan E ^a   Rustin, Gordon J S ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

CA125; ovarian cancer; PET; physical examination; secondary cytoreductive surgery; surveillance

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CA 125 ANTIGEN;

ASSAY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER RELAPSE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; FOLLOW UP; HORMONAL THERAPY; HUMAN; IMAGING; MEDICAL EXAMINATION; OVARY CANCER; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; RECURRENT DISEASE; REVIEW; SERUM; SYMPTOM; SYSTEMIC THERAPY; TREATMENT PLANNING; UNCERTAINTY;

DIAGNOSTIC IMAGING; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 77955425871     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32833ae8b6     Document Type: Review

References (33)

1. Duffy MJ, Bonfrer JM, Kulpa J, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 2005; 15:679-691.
2. Fehm T, Heller F, Kramer S, et al. Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients. Anticancer Res 2005; 25:1551-1554.
3. Prayer L, Kainz C, Kramer J, et al. CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer. J Comput Assist Tomogr 1993; 17:626-632.
4. Aebi S, Castiglione M. Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 (Suppl 2):ii14-ii16.
5. Chan KK, Tam KF, Tse KY, Ngan HY. The role of regular physical examination in the detection of ovarian cancer recurrence. Gynecol Oncol 2008; 110:158-161.
6. Menczer J, Chetrit A, Sadetzki S, et al. Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125 levels. Gynecol Oncol 2006; 103:137-140.
7. Shumsky AG, Stuart GC, Brasher PM, et al. An evaluation of routine follow-up of patients treated for endometrial carcinoma. Gynecol Oncol 1994; 55:229-233.
8. Tjalma WA,van Dam PA, Makar AP, CruickshankDJ. The clinical value and the cost-effectiveness of follow-up in endometrial cancer patients. Int J Gynecol Cancer 2004; 14:931-937.
9. Bradley EJ, Pitts MK, Redman CW, Calvert E. The experience of long-term hospital follow-up for women who have suffered early stage gynecological cancer: a qualitative interview study. Int J Gynecol Cancer 1999; 9:491-496.
10. van Der Burg ME, Lammes FB, Verweij J. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol 1990; 1:301-302.
11. Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 1996; 7:361-364.
12. Rustin GJ, MarplesM, Nelstrop AE, et al. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001; 19:4054-4057.
13. Wilder JL, Pavlik E, Straughn JM, et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol Oncol 2003; 89:233-235.
14. Prat A, Parera M, Adamo B, et al. Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels. Ann Oncol 2009; 20:294-297.
15. Rustin GJ, van Der Burg ME, on behalf of MRC and EORTC collaborators. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). J Clin Oncol 2009; 27 (Suppl):18s; abstract 1.
16. Gadducci A, Cosio S. Surveillance of patients after initial treatment of ovarian cancer. Crit Rev Oncol Hematol 2009; 71:43-52.
17. Buy JN, Moss AA, Ghossain MA, et al. Peritoneal implants from ovarian tumors: CT findings. Radiology 1988; 169:691-694.
18. Coakley FV, Choi PH, Gougoutas CA, et al. Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology 2002; 223:495-499.
19. Mitchell CL, O'Connor JP, Jackson A, et al. Identification of early predictive imaging biomarkersand their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy. Ann Oncol 2010. [Epub ahead of print].
20. Nanni C, Rubello D, Farsad M, et al. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Surg Oncol 2005; 31:792-797.
21. Thrall MM, DeLoia JA, Gallion H, Avril N. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol 2007; 105:17-22.
22. Risum S, Hogdall C, Markova E, et al. Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytor-eductive surgery. Int J Gynecol Cancer 2009; 19:600-604.
23. Fulham MJ, Carter J, Baldey A, et al. The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multicentre study as part of the Australian PET Data Collection Project. Gynecol Oncol 2009; 112:462-468.
24. Mangili G, Picchio M, Sironi S, et al. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging 2007; 34:658-666.
25. Gadducci A, Fuso L, Cosio S, et al. Are surveillance procedures of clinical benefit for patients treated for ovarian cancer? A retrospective Italian multi centric study. Int J Gynecol Cancer 2009; 19:367-374.
26. Tanner EJ, Chi DS, Eisenhauer EL, et al. Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias? Gynecol Oncol 2010; 117:336-340.
27. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 2009; 112:265-274.
28. Harter P, Du BoisA, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006; 13:1702-1710.
29. Oksefjell H, Sandstad B, Trope C. The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Ann Oncol 2009; 20:286-293.
30. Oskay-Oezcelik G, Du Bois A, Fasching P, et al. What do patients think about CA-125 monitoring in the follow-up? Results from a multicenter trial in 1,060 patients with ovarian cancer. J Clin Oncol 2009; 27:abstract 5522.
31. Markman M, Petersen J, Belland A, Burg K. CA-125 Monitoring in Ovarian Cancer: patient survey responses to the results of the MRC/EORTCCA-125 Surveillance Trial. Oncology 2010; 78:1-2.
32. Lewis R, Neal RD, Williams NH, et al. Nurse-led vs. conventional physician-led follow-up for patients with cancer: systematic review. J Adv Nurs 2009; 65:706-723.
33. Cox A, Bull E, Cockle-Hearne J, et al. Nurse led telephone follow up in ovarian cancer: a psychosocial perspective. Eur J Oncol Nurs 2008; 12:412-417